|
|
|
|
|
|
Fill-finish is one of the final steps before a drug product reaches patients, but teams often need to make the decisions that shape its success much earlier. As programs progress toward larger clinical studies and commercialization, aseptic processing requirements, technology transfer, equipment compatibility, capacity, and supply planning can introduce new risks to timelines and product quality.
A well-planned fill-finish strategy can help sponsors anticipate these challenges while creating a smoother path toward scale and commercial supply. In this edition of the Outsourced Pharma Capabilities Update (OPCU), explore how CDMOs are approaching sterile fill-finish across different stages of development, with perspectives on managing operational complexity, preparing for technology transfer, and building greater flexibility into future production. Watch the presentations below for practical considerations that can help strengthen your fill-finish strategy.
Recent Sessions Available On-Demand
AI Drug Manufacturing & Viral Vectors – October 2026
mRNA & Packaging, Labeling & Logistics – October 2026
Fill/Finish – October 2026
ADC – October 2026
Upcoming OPCU Topics & Times
Enabling ADC Success | 12/1/2026, PM Session
Mastering Aseptic Fill-Finish | 12/1/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
|
|
|
|
|
|
Thermo Fisher Scientific
|
Learn how to balance technical, regulatory, and supply chain considerations while avoiding costly late-stage changes and preparing for successful technology transfer, scale-up, and commercialization.
|
|
Request Information
|
|
Thermo Fisher Scientific
|
|
|
|
Lonza
|
Bastian Klöfer, Director of Commercial Development, Drug Product Services, explores Lonza's end-to-end biologics network, spanning drug substance, drug product development, manufacturing, analytics and regulatory support.
|
|
Request Information
|
|
Lonza
|
|
|
|
Simtra Biopharma Solutions
|
Explore new sterile manufacturing capacity for pre-filled syringes, lyophilized vials, and potent therapies, supporting flexibility, scale, and supply resilience.
|
|
Request Information
|
|
Simtra BioPharma Solutions
|
|
|
|
PCI Pharma Services
|
PCI integrates scalable manufacturing, packaging, device assembly, and global regulatory expertise to streamline tech transfer and strengthen supply chain resilience.
|
|
Request Information
|
|
PCI Pharma Services
|
|
|
|
Alcami
|
Discover critical considerations for sterile fill-finish, including manufacturability, scale-up, contamination control, and the path from clinical to commercial supply.
|
|
Request Information
|
|
Alcami
|
|
|
|
|